Form 4: Aligos Therapeutics Director James Paul Scopa Reports Stock Option Grant

Director James Paul Scopa reports the acquisition of stock options in Aligos Therapeutics.

Summary

• James Paul Scopa, a director of Aligos Therapeutics, Inc. (ALGS), reported a transaction involving stock options.
• On June 27, 2024, Scopa acquired stock options for 60,000 shares of ALGS common stock at an exercise price of $0.38.
• These options vest on the earlier of June 27, 2025, or immediately prior to the annual meeting in 2025, subject to continuous service.
• Following the transaction, Scopa directly owns 60,000 derivative securities.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of stock option grants, which is generally viewed neutrally to positively as it aligns director interests with shareholders. There are no red flags or negative implications.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Industry Context

This is a standard practice for incentivizing board members in publicly traded companies, particularly in the biotech industry.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry to align their interests with shareholders.
• The vesting schedule is typical, often tied to continued service and/or company performance milestones.
• Comparable companies like Gilead Sciences or Amgen also use stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates